Samarium-153 therapy for prostate cancer: The evaluation of urine activity, staff exposure and dose rate from patients


PARLAK Y., Gumuser G., Sayit E.

Radiation Protection Dosimetry, cilt.163, sa.4, ss.468-472, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 163 Sayı: 4
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1093/rpd/ncu237
  • Dergi Adı: Radiation Protection Dosimetry
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.468-472
  • Manisa Celal Bayar Üniversitesi Adresli: Evet

Özet

The aim of this study was to determine the excretion of Samarium-153-ethylenediaminetetramethylphosphonic acid (153Sm- EDTMP) in urine and to calculate the dose rate of its retention in the body as a function of time and the dose received by the skin of laboratory staff 's finger. Urine samples were collected from 11 patients after intravenous injection of 153Sm-EDTMP. The measurements of dose rate were performed. Thermoluminescent dosemeters were used for absorbed dose measurements. Effective half-lives that were calculated from urine sample measurements were found as 7.1±3 h within the first 24 h. Whole body dose rates before collecting urine of patients were 60.0 ± 15.7 μSv h21 for within 1 h following 153Sm-EDTMP administration. The highest finger radiation dose is to the right-hand thumb (3.8 ± 2 mGy). The results of the study imply that patients who recieved 153Sm-EDTMP therapy should be kept a minumum of 8 h in an isolated room at hospital and that one staff should give therapy at most two patients per week.